Follow-up of survivors of Diffuse Large B Cell Lymphoma (DLBCL), a non-Hodgkin lymphoma subtype

Follow-up includes scheduling regular review and ensuring cancer survivors are aware of the risks and symptoms of late effects associated with their cancer treatment.

Five- and 10-year survival (Australia)
Age is a factor in survival from non-Hodgkin lymphoma: young people’s survival rates are generally better than those of older people.

In 2004, five-year survival for people diagnosed with Diffuse Large B Cell Lymphoma in Victoria was 53% and 10-year survival was 46%. Figures have very likely improved substantially since then due to the introduction of rituximab.

Potential issues for survivors
Survivors may experience many different issues after completing treatment: physical, emotional, psychosocial and practical.

Survivorship care ideally addresses all of these issues. The four main aims of care during the survivorship phase, as detailed by the Institute of Medicine’s report (see Hewitt et al. 2006) ‘From cancer patient to cancer survivor: lost in transition’, are:

- surveillance for cancer spread, recurrence or second primary cancers and of other later effects
- coordination between specialists and primary care providers to ensure that all of the survivor’s health needs are met (incl. health promotion, immunisation, screening for cancer and non-cancerous conditions, and the care of concurrent conditions)
- intervention for consequences of cancer and its treatment (e.g. problems such as lymphoedema and sexual dysfunction, symptoms including pain and fatigue, psychological distress experienced by cancer survivors and their caregivers, and concerns related to employment and insurance)
- prevention of recurrent and new cancers, and of other late effects.

Surveillance for cancer spread or recurrence
Information in this section is based on the Victorian Government’s Patient Management Framework (Haematological Tumour Stream: Intermediate Grade non-Hodgkin Lymphoma).

The purpose of surveillance is to monitor the status of the disease and late adverse effects of therapy and to manage symptoms that arise following the initial treatment. Follow-up will depend on the:

- patient’s circumstances
- individual risk of relapse
- treatment intention if relapse should occur
- long-term risks associated with the initial treatment.

The frequency of follow-up immediately after treatment depends on the individual patient’s needs.

The surveillance schedule for recurrent / progressive disease is based on the intended therapy should disease recur, so there should be a clear decision about therapy for recurrent disease before the schedule is devised. Therapy may range from palliation (in which case intensive surveillance for early detection of asymptomatic disease is not warranted) to prompt and intensive intervention with curative intent.

Recurrence is usually detected by investigating new physical findings or symptoms or by using ‘non-specific’ systemic tests, such as serum lactate dehydrogenase. Asymptomatic recurrences are rarely detected by routine CT scans.

Which patients?
All patients who have been treated for non-Hodgkin lymphoma should be followed up. At times, follow-up may vary according to the treating Haematologist / Oncologist.
Follow-up of survivors of Diffuse Large B Cell Lymphoma (DLBCL), a non-Hodgkin lymphoma subtype

Review for cancer recurrence

<table>
<thead>
<tr>
<th>Timing of review</th>
<th>Review type</th>
<th>Consider also</th>
</tr>
</thead>
</table>
| For first 2–3 years after treatment: every 3 months | • Clinical assessment with a careful history and physical examination  
• Full blood examination  
• Lactate dehydrogenase assessment | Imaging studies, depending on the recurrence management plan:  
• frequency depends on patient’s risk  
• modality (CT or functional imaging) depends on region considered to be at risk and the presence of residual radiological abnormalities in which structural imaging may be less sensitive to minor changes. Consider structural versus functional imaging |
| For 4–5 years post-treatment: every 4–6 months |                                                                                       |                                                                                |


Note: this schedule may change, due for example to the detection of recurrence or the development of other illnesses. The schedule needs to be tailored to individual situations.

Specific screening and monitoring for late effects from treatment may also be needed, depending on the primary treatment, and, if radiation was incorporated, the doses used and fields treated. Consider:
- endocrine surveillance (pituitary, thyroid, gonadal) if irradiation to relevant areas was delivered
- cardiac assessment if anthracycline chemotherapy was used or mediastinal irradiation delivered
- osteoporosis if prolonged steroids administered or premature menopause / hypogonadism detected
- myelodysplasia
- renal function is ifosfamide or a platinum-analogue used
- secondary malignancies, particularly breast cancer in young females where radiation encompasses breast tissue
- melanoma and non melanoma skin cancer
- other haematological malignancies.

New symptoms: advice for survivors

Cancer survivors may wait to discuss some symptoms if they know a surveillance / follow-up appointment is scheduled. Advise the cancer survivor to contact their specialist cancer nurse or GP if they notice any new, persistent or unexplained symptoms.

Coordination between specialists and primary care providers

It is important that follow-up care is coordinated and that survivors are not required to attend excessive appointments.

Guidelines included in the Victorian Government’s Patient Management Framework (Haematological Tumour Stream: Intermediate Grade non-Hodgkin Lymphoma) advise that follow-up should be by a multidisciplinary team, although not all disciplines need to be involved in longer term follow-up.

They recommend that the primary treating clinician is best qualified to supervise and guide the follow-up of the patient, with input from the GP, other specialists and allied health practitioners as required.

Responsibility needs to be agreed between the primary treating clinician, the GP and the patient, with an agreed survivorship care plan documented, including notification to the GP or multidisciplinary team member if the patient does not attend follow-up appointments. The GP has a key role in follow-up.

Intervention for consequences of cancer and its treatment

Late effects of treatment for non-Hodgkin lymphoma

Note to cancer survivors: late effects from cancer treatment are generally uncommon and often rare. Do not assume that you will get a late effect if you had a treatment described here. Please speak to your doctor if you have any concerns about late effects from your cancer treatment.

Late effects can occur as a consequence of surgery, chemotherapy, and radiotherapy.

For survivors and their partners, there may be relationship effects from cancer and its treatment, including difficulties over changed roles and fear of recurrence. Some survivors may fear being a burden.

Survivors who go through and beyond cancer treatment without partners or close family and friends may experience great loneliness.
Follow-up of survivors of Diffuse Large B Cell Lymphoma (DLBCL), a non-Hodgkin lymphoma subtype

<table>
<thead>
<tr>
<th>Late effect</th>
<th>Cause / association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>Association with cancer treatment is not well understood; may occur in association with depression and anxiety</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Association with cancer treatment is not well understood; may occur in association with depression and anxiety</td>
</tr>
<tr>
<td>Cardiac toxicity</td>
<td>Anthracline-containing chemotherapy regimens, Mediastinal radiotherapy</td>
</tr>
<tr>
<td>Cardiac toxicity</td>
<td>Anthracline-containing chemotherapy regimens, Mediastinal radiotherapy</td>
</tr>
<tr>
<td>Cardiac toxicity</td>
<td>Anthracline-containing chemotherapy regimens, Mediastinal radiotherapy</td>
</tr>
<tr>
<td>Cardiac toxicity</td>
<td>Anthracline-containing chemotherapy regimens, Mediastinal radiotherapy</td>
</tr>
<tr>
<td>Lymphoedema</td>
<td>Surgical axillary / groin dissection or radiotherapy or both; This is not usually a major clinical problem</td>
</tr>
<tr>
<td>Premature menopause</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Depression and anxiety</td>
<td>Association with treatment is not well understood</td>
</tr>
<tr>
<td>Pain or discomfort</td>
<td>Surgery, chemotherapy and radiotherapy</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Impaired sexual functioning or sexual discomfort</td>
<td>Systemic therapy (esp. chemotherapy) leading to premature menopause / vaginal dryness</td>
</tr>
<tr>
<td>Impaired fertility</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Accelerated loss of bone density, fracture risk</td>
<td>Ovarian failure following chemotherapy. High-dose corticosteroids – (the mechanism is distinct from premature menopause)</td>
</tr>
<tr>
<td>Impaired cognitive functioning</td>
<td>Association with treatment is not well understood. May be associated with chemotherapy</td>
</tr>
<tr>
<td>Second primary cancer</td>
<td>Treatment for original cancer, including increased risk of cancer in areas exposed to radiation, increased risk of leukaemia due to use of some chemotherapy agents</td>
</tr>
<tr>
<td>Endocrine dysfunction (thyroid and pituitary gland)</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Raised cholesterol</td>
<td>Lifestyle choices and treatment</td>
</tr>
<tr>
<td>Increased risk of life threatening infection with encapsulated organisms</td>
<td>Asplenism / hyposplenism</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>General metabolic effects of chemotherapy (mostly platinum based compounds)</td>
</tr>
<tr>
<td>Melanoma and non-melanoma</td>
<td>Radiotherapy and intrinsic patient related factors</td>
</tr>
<tr>
<td>Other haematological malignancies</td>
<td>Chemotherapy</td>
</tr>
</tbody>
</table>
Follow-up of survivors of Diffuse Large B Cell Lymphoma (DLBCL), a non-Hodgkin lymphoma subtype

Further information related to late effects
Enquire about mood and whether the person feels they are coping. Assess survivor’s level of distress / depression. Psychological distress generally declines over time. Psychosocial interventions (e.g. support groups) may be effective. Support groups and / or contact with a fellow survivor through a service such as Blood Cancer Connect (contact via the Cancer Council Helpline on 13 11 20 or Leukaemia Foundation 1800 840240) may be helpful.

Prevention and detection of new cancers
Patients should be informed about the risks of developing another cancer as a result of their initial treatment (at the time of treatment as well as when treatment finishes). They should be advised that lifelong surveillance for secondary cancers is appropriate.

A management plan should be organised for surveillance relevant to each individual patient, with the patient, their family, the GP, and the specialist.

Follow-up care for all patients should include counselling about adopting healthy lifestyle behaviours. For example about improved diet, maintaining a healthy weight, smoking cessation and increasing physical activity as these may help to prevent a new primary cancer. They may also reduce many of the psychosocial consequences of cancer treatment.

Advise survivors (unless there are health reasons that indicate otherwise) to do at least 30 minutes of moderate-intensity physical activity on most, preferably all, days. The NH-MRC has produced dietary guidelines for Australian adults (information about the types and amounts of foods, food groups and dietary patterns that aim to promote health and well-being; reduce the risk of diet-related conditions, such as high cholesterol, high blood pressure and obesity; and reduce the risk of chronic diseases such as type 2 diabetes, cardiovascular disease and some types of cancers) on which advice to survivors can be based.

Advise regarding annual vaccinations including flu vaccine and Pneumococcal vaccination. Refer to Victorian Spleen Registry (03 9076 3928) email spleenregistry@alfred.org.au

Don’t neglect other aspects of primary health care. Where indicated, monitor survivors’ cholesterol, blood pressure and blood glucose. Survivors should have regular dental examinations and be counselled on routine sun protection.

Survivors need appropriate screening for other cancers at recommended time intervals. Mammography every two years is recommended for all women at average risk aged between 50 and 69. All women who have ever been sexually active should commence having Pap tests between the ages of 18 and 20 years, or 1 to 2 years after commencing sexual activity, whichever is later. In some cases screening for cervical cancer may be appropriate before 18 years of age. Women over 70 years of age who have had two normal Pap tests in the past five years do not require further Pap tests. If a woman over 70 years has never had a Pap test, or requests a Pap test, they should be screened. Patients over 50 years should be counselled regarding screening for bowel cancer. There is insufficient evidence for population-based screening for ovarian cancer; however, women who are at potentially high risk should be referred to a familial cancer clinic for assessment and management.

Further information
This overview was prepared with reference to:

- Available from www.petermac.org/cancersurvivorship

Australian Cancer Survivorship Centre
A Richard Pratt Legacy
Locked Bag 1, A’Beckett Street East Melbourne VIC 3002
Email: contactacsc@petermac.org
www.petermac.org/cancersurvivorship